<SEC-DOCUMENT>0001641172-25-014322.txt : 20250609
<SEC-HEADER>0001641172-25-014322.hdr.sgml : 20250609
<ACCEPTANCE-DATETIME>20250609163026
ACCESSION NUMBER:		0001641172-25-014322
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250603
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250609
DATE AS OF CHANGE:		20250609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CONDUIT PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001896212
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				873272543
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41245
		FILM NUMBER:		251034512

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL NORTH
		STREET 2:		SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		(646) 491 9132

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL NORTH
		STREET 2:		SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Murphy Canyon Acquisition Corp.
		DATE OF NAME CHANGE:	20211130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CDT="http://conduitpharma.com/20250603">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_CDT_conduitpharma.com_20250603 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20250603_20250603 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001896212 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000004" name="dei:EntityCentralIndexKey">0001896212</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cdt-20250603.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-06-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-03</xbrli:startDate>
        <xbrli:endDate>2025-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-03</xbrli:startDate>
        <xbrli:endDate>2025-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001896212</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-06-03</xbrli:startDate>
        <xbrli:endDate>2025-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; text-transform: uppercase"><b>FORM
<span id="xdx_905_edei--DocumentType_c20250603__20250603_zOl7IWr0Ool5"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span id="xdx_900_edei--DocumentPeriodEndDate_c20250603__20250603_z2oUSXkPMpj1"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">June 3, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20250603__20250603_zutAx3Vormm4"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000011" name="dei:EntityRegistrantName">Conduit
Pharmaceuticals Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250603__20250603_zEIGFDgsVlj4"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20250603__20250603_zuPxAZMIOlK5"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000013" name="dei:EntityFileNumber">001-41245</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20250603__20250603_zDYjK7TqYhz1"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-3272543</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20250603__20250603_zxBHCXpmT5P1"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000015" name="dei:EntityAddressAddressLine1">4851
    Tamiami Trail North</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressAddressLine2_c20250603__20250603_zn35jihln5D4"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCityOrTown_c20250603__20250603_z5gwSBcQ1NA7"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000017" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20250603__20250603_zFNVXQFUEhZh"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000018" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20250603__20250603_zIfV7rJu20Kb"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000019" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive
    offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--CityAreaCode_c20250603__20250603_zplORPj3BTM2"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000020" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>
<span id="xdx_904_edei--LocalPhoneNumber_c20250603__20250603_zvrZ04NerVZ7"><ix:nonNumeric contextRef="AsOf2025-06-03" id="Fact000021" name="dei:LocalPhoneNumber">491-9132</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Not
Applicable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20250603__20250603_zmcq7FIx1srd"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20250603__20250603_zE6wHJhuy8F7"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20250603__20250603_z2ZchlOypyOi"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20250603__20250603_zboc5OJMsgb4"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20250603__20250603__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zoANTRxZeRH2"><ix:nonNumeric contextRef="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.0001 par
    value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20250603__20250603__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zStNFTiIwNl8"><ix:nonNumeric contextRef="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember" id="Fact000027" name="dei:TradingSymbol">CDT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SecurityExchangeName_c20250603__20250603__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.0001ParValuePerShareMember_zKPDrf0g6f7f"><ix:nonNumeric contextRef="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market
    LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20250603__20250603__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_zuGJ7DiTPVGl"><ix:nonNumeric contextRef="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" id="Fact000029" name="dei:Security12bTitle">Redeemable Warrants, each
    whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20250603__20250603__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_z7vI38dy6cH"><ix:nonNumeric contextRef="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" id="Fact000030" name="dei:TradingSymbol">CDTTW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20250603__20250603__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_zKVxZCBp2Xyl"><ix:nonNumeric contextRef="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">The Nasdaq Stock Market
    LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250603__20250603_zJubONsEDW3a"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:booleantrue" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_902_edei--EntityExTransitionPeriod_c20250603__20250603_z7oTnnceM8lk"><ix:nonNumeric contextRef="AsOf2025-06-03" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 3, 2025, Conduit Pharmaceuticals Inc. (&#8220;Conduit&#8221;) entered into a joint development agreement (the &#8220;Joint Development
Agreement&#8221;) with Manoira Corporation (&#8220;Manoira&#8221;) for a term of one year, which will be automatically renewed for successive
one-year terms unless advance termination notice is provided in accordance with the terms of the Joint Development Agreement. Manoira
is an entity controlled by Dr. Andrew Regan, of which he is sole director. Dr. Regan is a director and the Chief Executive Officer of
Conduit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Joint Development Agreement, Conduit granted Manoira a non-exclusive, non-transferable, non-sublicensable, fully paid-up, royalty-free
license to the intellectual property rights related to the pharmaceutical compounds known individually and together as AZD1656 and AZD5658
(the &#8220;Conduit Assets&#8221;). Manoira will evaluate the Conduit Assets&#8217; applicability in animal health, explore veterinary
market opportunities, and provide data from the evaluations to inform Conduit&#8217;s human clinical programs. The license does not grant
Manoira the right to distribute, market, promote or sell the products or services that are related to or incorporate the Conduit Assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
June 3, 2025, in exchange for the approximate $500,000 of consideration to be paid by Conduit under the Joint Development Agreement,
Conduit issued to Manoira 154,799 shares of its common stock, par value $0.0001 (the &#8220;Common Stock&#8221;), (the &#8220;Consideration
Shares&#8221;) valued at the closing price of the Common Stock immediately preceding execution of the Joint Development Agreement. The
Consideration Shares are being offered in reliance upon an exemption from the registration requirement of the Securities Act of 1933,
as amended (the &#8220;Securities Act&#8221;), pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder,
and applicable state securities laws. The issuance of the Consideration Shares have not been registered under the Securities Act and
such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities
Act and any applicable state securities laws. Manoira is acquiring the Consideration Shares for its own account with the present intention
of holding the Consideration Shares for investment purposes and not with a view to or for sale in connection with any public distribution
of such securities in violation of any federal or state securities laws and is an &#8220;accredited investor&#8221; as defined in Regulation
D promulgated by the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
has agreed to use commercially reasonable efforts to prepare and file with the SEC a registration statement on Form S-3 (or any successor
form or, if Form S-3 is not available, another appropriate form) covering the resale of the Consideration Shares within 60 days after
the issuance of the Consideration Shares. Conduit will use commercially reasonable efforts to ensure that the registration statement
becomes effective within 60 days after filing and shall maintain the effectiveness of the registration statement until the earlier of:
(i) the date when Manoira has sold all Consideration Shares covered by the registration statement or (ii) the date when all Consideration
Shares may be sold without restriction pursuant to Rule 144 under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Joint Development Agreement does not purport to be complete and is qualified in its entirety by reference
to the full text of such agreement, which is attached hereto as Exhibit 10.1 to this Current Report on Form 8-K (the &#8220;Current Report&#8221;)
and is hereby incorporated by reference into this Item 1.01.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02 Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 of this Current Report is incorporated herein by
reference. Conduit issued the Consideration Shares in reliance upon an exemption from the registration requirement of the Securities
Act, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.
Conduit relied upon representations, warranties, certifications and agreements of Manoira in support of the satisfaction of the conditions
contained in Section 4(a)(2) of the Securities Act or Regulation D under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7.01. Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2025, the Company issued a press release announcing the Joint Development Agreement. The press release is furnished as Exhibit
99.1 and incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act,
whether made before or after the date hereof, except as expressly set forth by specific reference in such filing. The furnishing of this
information will not be deemed an admission as to the materiality of any information contained therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Forward-Looking
Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report includes forward-looking statements. These statements are made under the &#8220;safe harbor&#8221; provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as &#8220;will&#8221; and &#8220;expected&#8221;,
or the negative of such terms, or other comparable terminology, and include statements about the Joint Development Agreement and the
impacts, if any, on the Company. Forward-Looking statements are statements that are not historical facts. Such forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially
from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks, uncertainties
and other factors speak only as of the date of this Current Report, and the Company expressly disclaims any obligation or undertaking
to update or revise and forward-looking statement contained herein, or to reflect any change in our expectations with regard thereto
or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required
by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Joint Development Agreement, dated June 3, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release, dated June 4, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDUIT PHARMACEUTICALS INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    9, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Andrew
    Regan</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew Regan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1kk1OwzAQhU/QO4willGxI8oiuxIVhGihClXL1k0n1CLxRGP3hyNxS2xHoSwgshRl5j1/b0ZJkjR5oHvdIMPbXTmHFbZdoxxCiTUymgq9onh8ysG/S3zX1rEyLn4OxoK8B73ndiwqX4/Ko7a4y0HcXvuTTUDK/EbAdJGMQr8gU+sdGqdVA8rsYMnUsUan+LO/YaXOZKj9jKQ1stVkcpBj0be/IBMyg2c6qhPxh4X5vEhGaXxGyQPTofOq2dmhCU6YNdh6nO3dlxPTVAfrqM1L3CG2atvgRnGY0s5Utd/s6acwOyNX2gbJPfGLwde9Ynyp/QZaMq+Oqo/pIMIl68r3pBxPxALbLbJHSZFlUkzFsKaBCAMyBfRQOAUqnPoi4IULNTGQQbABDVRDD4dIB+X8Ogc9QhcyBNFVjPHH0L+ii7EQQi4Vr1VzwCVynO6f6L+pKVz1XugUwzG4ofM/Row4ML8BLdzBPA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
Development Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Joint Development Agreement, dated as of June 3, 2025 (this &ldquo;<U>Agreement</U>&rdquo;), is entered into by and between Conduit Pharmaceuticals
Inc., a Delaware corporation having an address at 4581 Tamiami Trail North, Suite 200, Naples, Florida 34103 (&ldquo;<U>Conduit</U>&rdquo;)
and Manoira Corporation, a Delaware Corporation having an address at c/o Corporation Service Company, 251 Little Falls Drive, Wilmington,
Delaware 19808 (&ldquo;<U>Manoira</U>&rdquo;). Conduit and Manoira may each be referred to herein as a &ldquo;<U>Party</U>&rdquo; and
collectively as the &ldquo;<U>Parties</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">1.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Background:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit is a dynamic, multi-asset clinical stage, life
science company delivering an efficient model for compound development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira is a specialty animal treatment company focused
on developing proprietary intellectual property using reformulation technology including co-crystallisation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit is the licensee and/or owner of certain intellectual
property rights related to certain pharmaceutical compounds known individually and together as AZD1656 and AZD5658 in all therapeutic,
prophylactic, palliative, and diagnostic uses in human and animals. (&ldquo;<U>AZD5658</U>&rdquo; together with AZD1656, the &ldquo;<U>Conduit
Assets</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parties wish to (i) jointly evaluate AZD1656 and
any of its derivatives, as well as AZD5658, in animal health indications, including generating preclinical data, (ii) analyze and explore
combination therapies in animal models, including combination therapies using the Conduit Assets together with Manoira&rsquo;s CBDA Cocrystal
(&ldquo;<U>Combination Therapies</U>&rdquo;) and (iii) produce translational data to inform Conduit&rsquo;s human clinical programs while
exploring veterinary market opportunities (collectively, the matters described in (i)-(iii) the &ldquo;<U>Development Activities</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    License Grant to Manoira. Effective as of the Effective Date, Conduit hereby grants to Manoira a non-exclusive, non-transferable,
    non-sublicensable, fully paid-up, royalty-free license under the Conduit Assets solely to the extent necessary for Manoira to conduct
    its Development Activities pursuant to this Agreement. The Research license does not grant Manoira the right to distribute, market,
    promote or sell the products or services that are related to or incorporate the Conduit Assets</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration;
Subject Shares:</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit is a publicly traded Company whose shares trade
on The Nasdaq Stock Market LLC trading under the symbol CDT. As consideration for the undertakings contained in this agreement, including
the services to be provided by Manoira hereunder, upon the Effective Date this agreement, Conduit will deliver to Manoira a total number
of shares equal to $500,000 divided by the latest closing price of Conduit&rsquo;s common stock (the &ldquo;<U>Subject Shares</U>&rdquo;).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From and after the date hereof, Manoira shall bear all
costs related to its obligations as set forth herein, including the cost of development of any Combination Therapies. Except for the
delivery of the Subject Shares, Conduit shall not be obligated to pay any consideration or expend any amounts under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira acknowledges that the Subject Shares are &ldquo;restricted
securities&rdquo; under the federal securities laws of the United States and applicable state securities laws since they are being acquired
from Conduit in a transaction not involving a public offering. Under such laws and applicable regulations such securities may be resold
without registration or qualification under the Securities Act of 1933, as amended (the &ldquo;<U>Act</U>&rdquo;), and applicable state
securities laws only in certain limited circumstances. The Subject Shares will contain restrictive legends or be subject to stop orders
reflecting the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the delivery of the Subject Shares
to Manoira, Manoira hereby represents and warrants to Conduit that (i) Manoira is acquiring the Subject Shares for its own account with
the present intention of holding the Subject Shares for investment purposes and not with a view to or for sale in connection with any
public distribution of such securities in violation of any federal or state securities laws, and (ii) Purchaser is an &ldquo;accredited
investor&rdquo; as defined in Regulation D promulgated by the Securities and Exchange Commission under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">e.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit shall use commercially reasonable efforts to
prepare and file with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) a registration statement on Form S-3
(or any successor form or, if Form S-3 is not available, another appropriate form) covering the resale of the Subject Shares within 60
days after the date of issuance of such Subject Shares. Conduit shall use commercially reasonable efforts to ensure that the registration
statement becomes effective within 60 days after filing and shall maintain the effectiveness of the registration statement until the
earlier of: (i) the date when Manoira has sold all Subject Shares covered by the registration statement or (ii) the date when all Subject
Shares may be sold without restriction pursuant to Rule 144 under the Act. Conduit shall bear all expenses incurred in connection with
the preparation, filing, and maintenance of the registration statement, including registration and filing fees, printing expenses, and
legal and accounting fees, except for any broker or underwriting fees or commissions related to Manoira&rsquo;s resale of the Subject
Shares. Manoira agrees to: (x) provide Conduit with all necessary information regarding its ownership of the Subject Shares and its intended
plan of distribution to be included in the registration statement; (y) notify Conduit promptly of any changes in such information and
(z) comply with all applicable securities laws in connection with the resale of the Subject Shares. Manoira&rsquo;s registration rights
under this <U>Section 2(e)</U> shall terminate when all Subject Shares issued to Manoira pursuant to this Agreement have been sold or
may be sold without restriction under Rule 144 of the Act. Conduit agrees to indemnify and hold harmless Manoira, its officers, directors,
employees, agents, and affiliates, from and against any losses, claims, damages, or liabilities arising out of or related to any untrue
statement or omission of a material fact in the registration statement, except to the extent such losses result from information provided
by Manoira for inclusion in the registration statement. Manoira agrees to indemnify and hold harmless Conduit and its officers, directors,
employees, agents, and affiliates to the extent any losses arise from untrue statements or omissions made by Manoira in connection with
its resale of the Subject Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira&rsquo;s
    Obligations: Manoira will be responsible for the following requirements:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira will provide staffing and facilities to conduct
the Development Activities. Manoira will conduct the Development Activities in a reasonable, customary and professional manner, in accordance
with clinical treatment protocols developed and overseen by qualified professionals. In coordination with Conduit, Manoira shall be responsible
for selecting the qualified professionals to perform the Development Activities and for ensuring such professionals perform the Development
Activities in a reasonable, customary and professional manner during the full term thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
    Costs:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parties agree that the costs (including attorney&rsquo;s
fees) of all Development Activities, including the cost of filing any and all patent applications and obtaining the issuance of any patents,
or the cost of protecting or registering any other intellectual property rights in the Development Activities or derived from the results
of the Development Activities shall be borne by Manoira.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent Conduit incurs costs that are to be borne
by Manoira pursuant to <U>Section 5(a)</U>, Conduit will invoice Manoira for such costs and such invoices will be paid promptly by Manoira
upon receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">6.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership
    of Intellectual Property Rights:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to Section 6(b), each Party shall own and retain
all right, title and interest in and to any and all: (a) information and inventions that are conceived, discovered, developed or otherwise
made solely by or on behalf of such Party or its Affiliates or its or their respective (sub)licensees, as applicable, under or in connection
with this Agreement, whether or not patented or patentable and any and all patents and other intellectual property rights with respect
thereto; and (b) other information, inventions, patents and other intellectual property rights that are owned or otherwise controlled
by such Party or its Affiliates or its or their (sub)licensees outside of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All intellectual property created pursuant to this Agreement
that is related to AZD1656 and AZD5658, including all know-how, derivatives, reports, and data related to any of the foregoing, shall
be solely owned and/or controlled by Conduit, regardless of inventorship (&ldquo;Conduit Foreground IP&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided in <U>Section 6(a)</U> and <U>(b)</U>, all intellectual property rights, including any patent rights, in the Combination
Therapies shall be jointly owned by the Parties (&ldquo;Joint Intellectual Property&rdquo;). All such intellectual property rights
and related data will be considered Confidential Information under the terms of this agreement unless and until such data is
published. Notwithstanding the foregoing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">i.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
    shall have the right to elect to solely own any and all such intellectual property rights relevant solely to human applications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">ii.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira
    shall have the right to elect to solely own any and all such intellectual property rights relevant solely to veterinary applications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">iii.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the extent that a Combination Therapy may be relevant to both human and veterinary applications, the Parties agree that Conduit shall
    have exclusive ownership to any registered jointly owned intellectual property in the field of human applications and Manoira shall
    have the exclusive ownership of the registered jointly owned intellectual property in the field of veterinary applications. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">iv.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
    parties shall have ownership of the data related to the Combination Therapies and may use such data to exploit their rights thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira shall promptly disclose to Conduit in writing
and shall cause its Affiliates and its and their (sub)licensees to so disclose, the development, making, conception or reduction to practice
of any Conduit Foreground IP or Joint Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">e.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit will have the first right (but not the obligation)
to control the enforcement, drafting, filing, prosecution and maintenance of (including the defense of any interference, opposition or
any other pre- or post-grant proceedings or challenges, including any patent term extensions) of all Conduit Foreground IP related patents,
using counsel of its own choice. Manoira will have the first right (but not the obligation) to control the enforcement, drafting, filing,
prosecution and maintenance of (including the defense of any interference, opposition or any other pre- or post-grant proceedings or
challenges, including any patent term extensions) of all Joint Intellectual Property related patents, using counsel of its own choice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">f.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira does hereby, assign, and shall cause its Affiliates
and its and their respective (sub)licensees to so assign to Conduit, without additional compensation, such right, title and interest
in and to any Conduit Foreground IP, as specified in Section 6(b), and Joint Intellectual Property, as specified by Section 6(c)(i),
as well as any intellectual property rights with respect thereto, to the extent required and not already effected by operation of law.
Manoira shall cause all persons who perform development activities or regulatory activities for it under this Agreement or who conceive,
discover, develop or otherwise make any information or inventions by or on behalf Manoira or its Affiliates or its or their respective
(sub)licensees under or in connection with this Agreement to be under an obligation to assign their rights in any information and inventions
resulting therefrom to Conduit, except where applicable law requires otherwise and except in the case of governmental, not-for-profit
and public institutions that have standard policies against such an assignment (in which case, a suitable license or right to obtain
such a license, shall be obtained). Conduit does hereby, assign, and shall cause its Affiliates and its and their respective (sub)licensees
to so assign to Manoira, without additional compensation, such right, title and interest in and to any Joint Intellectual Property, as
specified by Section 6(c)(ii), as well as any intellectual property rights with respect thereto, to the extent required and not already
effected by operation of law. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">g.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For so long as either Conduit or Manoira does not exercise
their respective right under <U>Section 6(c)</U> to solely own such respective intellectual property rights, either Party may seek to
exploit the applicable intellectual property rights, subject to the approval of the JSC, which shall determine the economic terms of
such use of the intellectual property rights as between Conduit and Manoira.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    of Agreement: The initial term of this agreement will be one (1) years from the Effective Date first set forth above. Upon the expiration
    of the initial term, this agreement will automatically renew for successive one (1) year renewal terms unless either Party gives
    the other Party not less than sixty (60) days written notice of its intent not to renew this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either Party may terminate this agreement upon a material
breach of the other Party which breach is not cured within thirty (30) days after written notice of breach is given to the breaching
party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon expiration of the initial term of this agreement,
either Party may terminate this Agreement at any time upon sixty (60) days written notice to the other Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either Party may terminate this agreement upon sixty
(60) days written notice to the other Party, if, in such Party&rsquo;s reasonable good faith determination, the Development Activities
conducted show that: (i) the products and methods being evaluated are not reasonably viable or effective for commercialization; (ii)
the cost, time and effort involved in further development of the products and methods being evaluated show that the project is not scientifically
or economically viable or that further efforts in this regard are not economically, medically or otherwise justifiable or (iii) the Development
Activities have been completed in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit may terminate this agreement immediately if
Manoira files, or threatens to file, an action challenging the validity or enforceability of a patent related to the Conduit Assets or
the Conduit Foreground Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">9.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    Sharing; Confidentiality:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Party shall provide the other Party access to a
data room that includes all of the information of such Party required by the other Party to fulfill its obligations hereunder. The data
room shall be updated on a quarterly basis. Without limiting the foregoing, Manoira shall provide Conduit with access to, and joint ownership
of, all preclinical data generated from Manoira&rsquo;s animal health studies, to ensure that Conduit has full access for Conduit&rsquo;s
human clinical programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; color: #010000"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">b.
</FONT>In connection with this Agreement, each Party may disclose to the other Party, or permit the other Party to have access to, information
that is confidential and proprietary to the disclosing Party (the &ldquo;<U>Confidential Information</U>&rdquo;). Confidential Information
includes but is not limited to the Conduit Assets, the Development Activities, know-how, business or marketing strategies related thereto,
plans for research and development, development tools, financial information, production costs and information, and supplier and customer
lists and information and medical research conducted during the performance of this agreement. Confidential Information further includes
any information identified or marked as &ldquo;Confidential,&rdquo; &ldquo;Proprietary,&rdquo; or similarly marked. The terms of this
Agreement will also be considered Confidential Information.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither Party will copy, reproduce, disclose, disseminate
or provide any Confidential Information to any third party, without the prior written consent of the disclosing Party. In addition, the
Parties agree that they will use the Confidential Information only for the purpose of carrying out their obligations under this Agreement.
Upon termination of this Agreement for any reason, any recipient will return to the disclosing Party all Confidential Information and
any copies of it and will remove and delete any such Confidential Information for any computers, computer systems or other electronic,
magnetic or optical media in its possession or control, provided, however that in no event will any recipient be required to erase, destroy
or return electronic information stored on backup tapes or similar electronic data processing systems made in the ordinary course of
business, so long as the Confidential Information is retained in accordance with the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing in this agreement will prevent any Party from
dealing with its own Confidential Information in any manner it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">e.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the above, the following materials will
not be deemed confidential:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    which was in the public domain at the time of disclosure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    which was published or otherwise became part of the public domain after disclosure to the applicable Party through no fault of such
    Party; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    which was received from a third party who did not acquire it, directly or indirectly, from a Party under an obligation of confidence.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">10.
</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Steering Committee:</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parties hereby establish a joint steering committee
(the &ldquo;<U>Joint Steering Committee</U>&rdquo; or the &ldquo;<U>JSC</U>&rdquo;) to oversee and coordinate the Development Activities
and commercialization of the Combination Therapies, and to encourage and facilitate the ongoing cooperation and communication between
the Parties regarding matters related to such activities. The Parties agree to act in accordance with the determinations of the JSC in
the performance of their respective obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without limiting the foregoing, the JSC shall (i) monitor
progress of the Development Activities and the development and commercialization of the Combination Therapies, review relevant data produced
in the conduct of such activities and timely share information on progress of such activities with the Parties, (ii) decide whether to
advance, suspend, or terminate any such activities, (iii) Coordinate the Parties&rsquo; activities with respect to the commercialization
of any Combination Therapies, (iv) upon commercialization of new Combination Therapies, identify and work with an independent, third-party
commercialization counterparty to commercialize the Combination Therapies on terms, including with respect to revenue sharing, acceptable
to the JSC, (v) serve as a forum for the discussion of any safety, scientific or technical concerns regarding such activities; (vi) attempt
to resolve any disputes on matters within the JRC&rsquo;s authority on an informal basis and in good faith prior to the initiation of
escalation or other formal dispute resolution mechanisms hereunder; and (vii) perform such other activities as the Parties agree in writing
shall be the responsibility of the JRC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The JSC shall consist of four (4) members, with two
(2) appointed by Conduit and two (2) appointed by Manoira, each of whom shall have relevant credentials, experience, knowledge, and authority
within such Party&rsquo;s organization. Within thirty (30) days following the Effective Date, each Party shall designate its initial
members to serve on the JSC. Each Party may replace its representatives on the JSC by written notice to the other Party. The Parties
shall alternate, on a meeting by meeting basis, in appointing one (1) of their representatives on the JSC to act as the chairperson of
the JSC for the meeting. The chairperson shall prepare and circulate agendas prior to each JSC meeting and subsequently, promptly provide
to the Parties drafts of the minutes of each such meeting. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The JSC shall hold meetings at such times as it elects
to do so, but in no event shall such meetings be held less frequently than once every quarter. Meetings of the JSC may be held in person,
by audio or video teleconference; provided that at least one (1) meeting per year of the JSC shall be held in person. In-person JSC meetings
shall be chaired by a JSC representative of the Parties on an alternating basis and held at locations selected on an alternating basis
by the Parties, with the first in-person JSC meeting to be chaired by a Conduit representative and held at a location to be selected
by Conduit. Each Party shall be responsible for all of its own expenses in connection with participating in the JSC meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">e.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All decisions of the JSC shall be made by unanimous
vote, with each Party&rsquo;s representatives collectively having one (1) vote. No vote of the JSC may be taken unless at least one of
each Party&rsquo;s representatives is present for the vote. Each Party shall be responsible for ensuring that, at all times, its representatives
on the JSC act reasonably and in good faith in carrying out their respective responsibilities hereunder. If the JSC cannot reach consensus
with regard to any matter within its authority within ten (10) Business Days after such matter has been brought to the JSC&rsquo;s attention,
such matter shall be referred to the Chief Executive Officer of each Party, who shall promptly meet and attempt in good faith to resolve
such issue within ten (10) Business Days from the date upon which such matter is referred to them. In the event that such Chief Executive
Officers are unable to resolve such issue within ten (10) Business Days of the issue being referred to them, then such dispute shall
be resolved in accordance with <U>Section 14</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">f.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitation on JRC Authority. The JRC shall conduct its
activities in good faith and shall not have the power to (i) amend or modify the Parties&rsquo; respective rights and obligations under
this Agreement or otherwise alter the scope of the Agreement, (ii) waive either Party&rsquo;s compliance with the terms and conditions
of this Agreement, (iii) determine any issue in a manner that would conflict with the express terms and conditions of this Agreement,
or (iv) resolve any dispute between the Parties regarding such rights and obligations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">g.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses. Each Party shall be responsible for all costs
and expenses for its members and other representatives to attend meetings of, and otherwise participate in, the JRC and any subcommittees
and project teams, including all travel and related costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">11.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Contractors: It is understood that both Parties are independent contractors and engage in the operation of their own respective businesses.
    Neither Party will be considered the agent of the other Party for any purpose whatsoever nor does any Party have any authority to
    enter into any contract or assume any obligation for the other Party or to make any warranty or representation on behalf of the other
    Party. Each Party is fully responsible for its own employees, servants and agents, and the employees, servants and agents of one
    Party will not be deemed to be employees, servants and agents of the other Party for any purpose.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">12.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Announcements: No Party will make any public disclosure or public announcement of any information related to this agreement without
    the prior consent of the other Party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">13.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment:
    No party may assign this agreement or any rights or obligations under this agreement without the prior consent of the other party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">14.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dispute
    Resolution. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The parties intend to negotiate in good faith and resolve any dispute arising under this Agreement. In the event the parties are unable to resolve any such dispute, including any dispute referenced in <U>Section 10(e)</U>, the Parties shall confer to jointly select a mediator to be administered by the New York, New York office of Judicial Arbitration &amp; Mediation Services, Inc. or its successor (&ldquo;<U>JAMS</U>&rdquo;) or any other office of JAMS agreed to by the Parties, in accordance with JAMS&rsquo;s mediation procedures in effect on the date of the Agreement. If the Parties cannot agree on the selection of a mediator, the Party asserting the dispute shall file a request in writing for the appointment of a mediator with the New York, New York office of JAMS who is an experienced intellectual property attorney knowledgeable in the field of intellectual property law relating to the Development Activities with a copy of the request being served on the other Party, and the mediation shall be conducted by the appointed mediator. The cost of such mediation shall be shared equally by the Parties. If no agreement is reached by the Parties following a good faith mediation in accordance with the aforementioned provisions, the dispute shall be submitted to binding arbitration before JAMS, at its office located in New York, NY, or any other office of JAMS agreed to by the Parties pursuant to the Federal Arbitration Act, 9 U.S.C. Sec. 1 et sec. Either Party may commence such arbitration by filing a written demand for arbitration with JAMS, with a copy to the other Party. The arbitration will be conducted in New York, New York, in accordance with the provisions of JAMS Streamlined Arbitration Rules and Procedures in effect at the time of filing of the demand for arbitration. The Parties will cooperate with JAMS and each other in selecting an arbitrator from JAMS panel of neutrals, and in the prompt scheduling and completion of the arbitration proceedings. If the parties cannot agree on the arbitrator within ten days after receipt of a panel of neutrals from JAMS, JAMS shall appoint the arbitrator from its panel of neutrals who is an experienced intellectual property attorney knowledgeable in the field of intellectual property law relating to the Development Activities. Any costs and legal fees associated with such arbitration shall be borne as determined by the arbitrator. Judgment on the arbitration award may be entered in any federal or state court in New York, New York. Both parties consent to the jurisdiction of such courts. The parties agree that any such dispute and all information concerning such dispute shall be kept confidential and shall be subject to the provisions of <U>Section 9</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 81pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo --> 8<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, any Party may seek and
obtain emergency or preliminary equitable or injunctive relief from any court of competent jurisdiction in order to prevent irreparable
injury or to preserve the status quo pending any ruling in arbitration. In any action seeking equitable or injunctive relief pursuant
to this paragraph (and notwithstanding any arbitration rule to the contrary), the Court (rather than the arbitrator) will have the power
to determine any questions of its jurisdiction or authority to issue such a ruling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">15.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Provisions:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">a.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclaimer of Warranties. Neither Party makes any representations
or grants any warranties, express or implied, either in fact or by operation of law, by statute or otherwise and each Party specifically
disclaims any other warranties, whether written or oral or express or implied, including any warranty of quality, merchantability or
fitness for a particular use or purpose or any warranty as to the validity of any patents or the non-infringement of any intellectual
property rights of Third Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">b.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification: This agreement may only be modified by
an agreement in writing signed by both Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">c.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts: This agreement may be executed in one
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">d.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices. All notices and communications required under
this Agreement will be in writing and will be delivered in person, or mailed, postage prepaid, by overnight express carrier, to the address
of the parties listed at the beginning of this Agreement, or to any other address as such Party designates in a written notice to the
other Party. All notices sent pursuant to the terms of this section will be deemed received on the date of delivery if personally delivered,
or if sent by overnight express carrier, on the next business day immediately following the day sent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">e.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability. The provisions of this Agreement will
be deemed severable and the invalidity or unenforceability of any provision will not affect the validity or enforceability of any other
provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">f.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law. This Agreement shall be governed in all
respects by the laws of the United States and the State of New York, except for conflict of laws provisions. The parties agree that for
any dispute, controversy or claim arising out of or in connection with this Agreement, venue and personal jurisdiction shall be in the
federal or state court with competent jurisdiction located in New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">g.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire Agreement. This Agreement constitutes and expresses
the entire agreement and understanding between the parties hereto with respect to the subject matter, all revisions discussions, promises,
representation, and understanding relative thereto, if any, being herein merged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Purchase Agreement to be duly executed as of the date first written above:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONDUIT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit Pharmaceuticals Inc., a</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware corporation</FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Bligh&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Bligh</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
    CFO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>MANOIRA</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira Corporation, a</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware Corporation</FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew Regan</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Regan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[Signature
Page to Joint Development Agreement]</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conduit
Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Collaboration
    leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks
    to capture commercial potential in the $15 billion animal health market </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Evaluation of AZD5658
    expands Conduit&rsquo;s glucokinase activator platform into novel veterinary applications, complementing AZD1656 development</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cost-efficient approach
    enhances Conduit&rsquo;s pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Synergistic combination
    therapies under evaluation could redefine treatment standards in veterinary and human applications</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAPLES,
Fla. and CAMBRIDGE, United Kingdom, June 4, 2025 (GLOBE NEWSWIRE) &mdash; Conduit Pharmaceuticals Inc. (Nasdaq: <U>CDT</U>) (&ldquo;Conduit&rdquo;
or the &ldquo;Company&rdquo;) today announced that it has entered into a joint development agreement with Manoira Corporation (&ldquo;Manoira&rdquo;),
a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics
for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Conduit&rsquo;s
AZD1656 and AZD5658, both clinical-stage glucokinase activators, in animal health indications, providing Conduit with high-value translational
data across human and veterinary applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira
will focus its initial evaluation of AZD1656 in animal osteoarthritis, a common degenerative joint condition in companion animals, to
generate preclinical data that will better inform Conduit&rsquo;s human clinical programs. Notably, early animal studies conducted by
AstraZeneca suggest that glucokinase activators may have therapeutic potential in osteoarthritis<SUP>1</SUP>. In addition, Manoira
plans to evaluate a novel combination of its patented CBDA co-crystal with AZD1656 and AZD5658 for the treatment for osteoarthritis in
animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
cost-efficient collaboration allows Conduit to accelerate its understanding of AZD1656&rsquo;s mechanism of action, safety profile, and
potential efficacy across species, while retaining 100% ownership of all data and intellectual property generated relating to AZD1656
and AZD5658 for human applications. The partnership not only enhances Conduit&rsquo;s core human therapeutic pipeline but also opens
potential new revenue streams in the high-growth veterinary market, creating a dual-track value proposition for its shareholders. The
parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed
as a result of any such findings. Additionally, Manoira will evaluate AZD5658 for veterinary applications, expanding the utility of Conduit&rsquo;s
glucokinase activator portfolio and supporting cross-species insight generation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategic
and Financial Benefits for Conduit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
joint development agreement underscores Conduit&rsquo;s commitment to innovative, high-return collaborations that maximize resource efficiency
and pipeline potential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost-efficient
    preclinical data to de-risk and accelerate human clinical trials, potentially reducing development timelines and costs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-species insights
    that enhance the probability of success for AZD1656 in human indications, strengthening Conduit&rsquo;s competitive edge in glucokinase
    activator therapies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
<U>https://patentscope.wipo.int/search/en/WO2009022179</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entry into
    the estimated $15 billion animal health market, projected to grow at a CAGR of 6.5% through 2027<SUP>2</SUP>, driven by rising
    pet ownership, increasing demand for advanced veterinary therapies, and expanding livestock health investments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 23.9pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
transformative agreement with Manoira exemplifies our strategy of creating value through innovative collaborations,&rdquo; said Dr. Freda
Lewis-Hall, Chair of Conduit Pharmaceuticals. &ldquo;By leveraging Manoira&rsquo;s reformulation expertise in animal health, we are accelerating
AZD1656&rsquo;s development, unlocking new commercial opportunities, and generating critical data to drive our human clinical programs
- all while maintaining full control of our intellectual property relating to AZD1656 and AZD5658. The inclusion of AZD5658 further demonstrates
our intention to explore cross-species value through targeted, capital-efficient programs. Together, these efforts position Conduit as
a cross-species leader in innovative, cost-efficient drug development.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Agreement, Conduit will retain all existing intellectual property (&ldquo;IP&rdquo;) and will retain exclusive rights
and ownership of all new IP relating to AZD1656 and AZD5658 for human applications. Manoira has agreed to fund all of the development
activities of the collaboration and, in lieu of any further obligation for development costs, Conduit has agreed to issue Manoira an
up-front consideration of $500,000 to be settled solely through the issuance of 154,799 shares of common stock (based on the closing
price per share of $3.23 on June 3, 2025). Manoira is an entity controlled by Dr. Andrew Regan, of which he is sole director. Dr. Regan
is a director and the Chief Executive Officer of Conduit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Manoira Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manoira
Corporation specializes in the development of innovative products designed specifically for the optimum treatment of companion animals
and livestock &ndash; either developed internally or sublicensed from leading pharmaceutical partners. Its current pipeline includes
products for pain, inflammation, nausea and anxiety, including a patented cocrystal form of cannabidiolic acid (CBDA) where enhanced
stability and precise dosing enables products specifically tailored for individual animal requirements. With a robust 20-year patent
covering CBDA products based on solid form technologies such as co-crystallization, Manoira maintains a strong intellectual property
position and a sustainable competitive edge in the animal health sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Conduit Pharmaceuticals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduit
is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires
and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial
intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by
a highly experienced team of pharmaceutical executives including Dr. Andrew Regan and Dr. Freda Lewis-Hall, this novel approach is a
departure from the traditional pharma/biotech business model of taking assets through regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP><U>
https://www.globenewswire.com/news-release/2022/11/10/2553101/0/en/Veterinary-Vaccines-Market-Size-to-Gain-15-Billion-by-2028-with-6-5-CAGR-Exclusive-Report-by-The-Insight-Partners.htm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than
statements of historical facts contained in this press release, including statements regarding Conduit&rsquo;s future results of operations
and financial position, Conduit&rsquo;s business strategy, prospective product candidates, product approvals, research and development
costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated
studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking
statements. These forward-looking statements generally are identified by the words &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;strategy,&rdquo; &ldquo;future,&rdquo; &ldquo;opportunity,&rdquo;
&ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;will be,&rdquo; &ldquo;will
continue,&rdquo; &ldquo;will likely result,&rdquo; and similar expressions. These forward-looking statements are subject to a number
of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit&rsquo;s securities
on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected
by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key
employees; the risks that Conduit&rsquo;s product candidates in development fail clinical trials or are not approved by the U.S. Food
and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility
that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to
be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September
2023, including those under &ldquo;Risk Factors&rdquo; therein, and in other filings made by Conduit with the U.S. Securities and Exchange
Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit&rsquo;s
control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by
law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors
&amp; Media:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>info@conduitpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cdt-20250603.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6ASbP9z5Z8KekhvWB1bVnKXy8iw8p4oyJwdiVGEeYG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:CDT="http://conduitpharma.com/20250603" elementFormDefault="qualified" targetNamespace="http://conduitpharma.com/20250603">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://conduitpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20250603_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20250603_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cdt-20250603_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="CDT_CommonStock0.0001ParValuePerShareMember" name="CommonStock0.0001ParValuePerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" name="RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>cdt-20250603_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20250603.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cdt-20250603.xsd#CDT_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_CDTCommonStock0.0001ParValuePerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTCommonStock0.0001ParValuePerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cdt-20250603.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cdt-20250603_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20250603.xsd#CDT_CommonStock0.0001ParValuePerShareMember" xlink:label="CDT_CommonStock0.0001ParValuePerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_CommonStock0.0001ParValuePerShareMember" xlink:to="CDT_CommonStock0.0001ParValuePerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_CommonStock0.0001ParValuePerShareMember_lbl" xml:lang="en-US">Common Stock, $0.0001 par value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="cdt-20250603.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:to="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member_lbl" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cdt-20250603_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://conduitpharma.com/role/Cover" xlink:href="cdt-20250603.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://conduitpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cdt-20250603.xsd#CDT_CommonStock0.0001ParValuePerShareMember" xlink:label="loc_CDTCommonStock0.0001ParValuePerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTCommonStock0.0001ParValuePerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cdt-20250603.xsd#CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:label="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CDTRedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001641172-25-014322-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-014322-xbrl.zip
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MG87;ON(6+XE4(KH,N@^HO/.P%FFT"=7,P>F86S=&C(6(WN(-%Q4F9)&MT+Y
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M& #S!HUPNG+X:OO\8H'XJ<92%PKH-EA@)PWI?^;XL=F1[YNE)O&<@ 5(  [
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M>BFJ)H#FXAVQ(@GT122"9"JF[Y=7-UWQ7WRSVL3_FN.4\"W_!U!+ P04
M" #+@\E:K&E:M6H(  ##8P  %    &-D="TR,#(U,#8P,U]P<F4N>&ULU9W?
M<]NX$<??.]/_@:<^ZY>=Y!I?W!M'MFXTET0^RY>T?<E )"1A# $: +2E_[X
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M0 4K*'3<9-*GKF;(7^2C(NZ=%I/-<BJY?V=-J2$4-6[J&-!8,^TC/\HYGYA
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M,MC^[GFJ8+>/8+F@%2:Q+S6\/;GC ;6>WH4O]'QL4FKU\6""+F>844$SE F
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MWT\U$CS<ZHP42#N]D"$NH(""T"+]EP5R\XINK&^DJDF9?\0S+'D?+I&BY=F
M\;E"S"T_01=(TDM#]E@.&Z\H&MQXO^'"?-JWOEC/F8H2&VU\%UQE\ BO'K9"
ME;0IHFV %CU/BC64BXO'YVC/8Y2^1:I(KK?T /8*\WY;?_*Z<WD2["WWD<N
M5'"31D%=(-A(- ;F@J1-$#OP5T!GL_?O?8+NP2MNP;Z5TC%/>I2:SW&MPY[S
M\=;# ,/QR/.$('.6+_R\I_>12PL! /=8H ]GE>KL1B,#;-V**T+;F+B$-BJ,
M1$2:E^/1YXB6I^G(55;<HE5WKQ">I1<9G@^>/ZJ9 8(F4V1L3B>FZX-@=+A
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M(-C!%O,_<O*OJ\HVO32DPSA[S\-&M<IB.MB&U"#ROX)"J4ZG5/L994?3$8@
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M7U$QHC]*XO]*"?TQD_\'4$L#!!0    ( ,N#R5IYD/!YY!T  -C1   +
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MGB9O9-NUQ'E+:/]=)4XQ6>(T'<=C_%&YT[/4<NO+J3/H/7N;P$-RI_R W%F
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M;)/;<R;T(E?B1#*.B<<G1*[,B2[,S[P2YQEK%8!FBTN7(E A/!^A^SL/:Y$
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MMG,]2YOBSZ$[,O;_'U!+ 0(4 Q0    ( ,N#R5H9.9/NZ@,  $D/   0
M          "  0    !C9'0M,C R-3 V,#,N>'-D4$L! A0#%     @ RX/)
M6DX%3TX?"0  *6D  !0              ( !& 0  &-D="TR,#(U,#8P,U]D
M968N>&UL4$L! A0#%     @ RX/)6L9AA(XT#   6I$  !0
M ( !:0T  &-D="TR,#(U,#8P,U]L86(N>&UL4$L! A0#%     @ RX/)6JQI
M6K5J"   PV,  !0              ( !SQD  &-D="TR,#(U,#8P,U]P<F4N
M>&UL4$L! A0#%     @ RX/)6M+.V= ],   UFP!  H              ( !
M:R(  &5X,3 M,2YH=&U02P$"% ,4    " #+@\E:DTL__+\3  #39   "@
M            @ '04@  97@Y.2TQ+FAT;5!+ 0(4 Q0    ( ,N#R5IYD/!Y
MY!T  -C1   +              "  ;=F  !F;W)M."UK+FAT;5!+!08
.!P ' *T!  #$A      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CDT="http://conduitpharma.com/20250603"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cdt-20250603.xsd" xlink:type="simple"/>
    <context id="AsOf2025-06-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
        </entity>
        <period>
            <startDate>2025-06-03</startDate>
            <endDate>2025-06-03</endDate>
        </period>
    </context>
    <context id="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:CommonStock0.0001ParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-03</startDate>
            <endDate>2025-06-03</endDate>
        </period>
    </context>
    <context id="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001896212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-03</startDate>
            <endDate>2025-06-03</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-06-03" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-06-03" id="Fact000004">0001896212</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-06-03" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-06-03" id="Fact000010">2025-06-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-06-03" id="Fact000011">Conduit Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-06-03" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-06-03" id="Fact000013">001-41245</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-06-03" id="Fact000014">87-3272543</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-06-03" id="Fact000015">4851     Tamiami Trail North</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-06-03" id="Fact000016">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-06-03" id="Fact000017">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-06-03" id="Fact000018">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-06-03" id="Fact000019">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-06-03" id="Fact000020">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-06-03" id="Fact000021">491-9132</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-06-03" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-06-03" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-06-03" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-06-03" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000026">Common Stock, $0.0001 par     value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000027">CDT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-06-032025-06-03_custom_CommonStock0.0001ParValuePerShareMember"
      id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000029">Redeemable Warrants, each     whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000030">CDTTW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-06-032025-06-03_custom_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-06-03" id="Fact000032">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-06-03" id="Fact000033">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 03, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  03,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Conduit
Pharmaceuticals Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001896212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-3272543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4851
    Tamiami Trail North<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-9132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CDT_CommonStock0.0001ParValuePerShareMember', window );">Common Stock, $0.0001 par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par
    value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each
    whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTTW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CDT_CommonStock0.0001ParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CDT_CommonStock0.0001ParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://conduitpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cdt-20250603.xsd</File>
    <File>cdt-20250603_def.xml</File>
    <File>cdt-20250603_lab.xml</File>
    <File>cdt-20250603_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "CDT",
   "nsuri": "http://conduitpharma.com/20250603",
   "dts": {
    "schema": {
     "local": [
      "cdt-20250603.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "cdt-20250603_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cdt-20250603_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdt-20250603_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://conduitpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-03",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "auth_ref": []
    },
    "CDT_CommonStock0.0001ParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20250603",
     "localname": "CommonStock0.0001ParValuePerShareMember",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.0001 par value per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "CDT_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://conduitpharma.com/20250603",
     "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://conduitpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
